These TDN delivery platforms were developed for the extracellular release of apt‐PD‐L1 in response to weakly acidic tumor conditions, blocking PD‐L1 receptors on tumor cells while enabling CpG uptake by immune cells to stimulate an immune response. This evidence concerns the gene CD274 and neoplasm.